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Abstract
The work in the thesis entitled “Design, Synthesis and Biological Evaluation of New Pyrrolo[2,1-c][1,4]benzodiazepines as Antimitotic and Anticancer Agents” has been undertaken with an aim to synthesize new pyrrolo[2,1-c][1,4] benzodiazepine analogues and their dimers, to explore their DNA binding activity and anticancer activity. In recent years combination chemotherapy with different mechanisms of action is one of the methods that is being adopted to treat cancer. Therefore, a single molecule containing more than one pharmacophore, each with different modes of action could be beneficial for the treatment of cancer. The work carried out has been described in four chapters.
CHAPTER-I: This chapter contains general introduction on cancer and chemotherapy, covalent interactions of drug with DNA, particularly by pyrrolo[2,1-c][1,4]benzodiazepine (PBD) antitumour antibiotics. It also gives an introduction to the objectives of present work. 
CHAPTER-II: This chapter deals with general introduction to chemotherapeutic anticancer agents and classification based on their mode of action (mechanism), particularly inhibition of tubulin polymerization and effect on cell cycle process. Recent developments in the area of PBD analogues with different mechanisms have been demonstrated, followed by the description of design, synthesis and biological evaluation of a new class of cinnamido linked pyrolobenzodiazepine hybrids and their dimers. Their antimitotic activity, inhibition of tubulin polymerization and effect on cell cycle process has been investigated and these results are discussed.
CHAPTER-III: This chapter illustrates the introduction on dendrimers and its biological importance in the field of medicinal chemistry. Dendrimers have the ability to improve solubility, enhance anticancer activity and most importantly act as drug carriers. This study describes the synthesis, DNA-binding ability and anticancer of C8 linked G1 dendrimer-pyrrolobenzodiazepine conjugates.
CHAPTER-IV: This chapter describes the design, synthesis, DNA binding affinities and anticancer activity of some new hybrids of 1,4-diarylimidazolinones and pyrrolo[2,1-c][1,4] benzodiazepines.
CHAPTER-I
General introduction on cancer
Cancer is a group of more than 100 different diseases sharing the common characteristic of abnormal cellular division that is not subject to normal growth controls. Cancer occurs when cells become abnormal and keep dividing and forming more cells without control or order. All organs of the body are made up of cells. Normally, cells divide to produce more cells only when the body needs them. If cells divide when new ones are not needed, they form a mass of excess tissue, called a tumor. Tumors can be benign or malignant. Often, benign tumors can be removed by surgery, and they are not likely to return. However malignant tumors are cancerous. They have a tendency to spread, invade and destroy nearby tissues and organs. Cancer cells can also break away from a malignant tumor and travel through the bloodstream (leukemia) or the lymphatic system (lymphoma) to form new tumors in other parts of the body. The spread of cancer is called metastasis. Prognosis of cancer has improved greatly in modern times owing to treatment advances and early detection programs. However, although survival rates have improved, cancer still remains the 2nd top cause of death, second only to heart disease in the United States and is a major public health problem in the other developed countries. The rate of its induction throughout the world is increasing every year, making it a challenging area for major focus for both physicians as well as scientists.


Types of treatment for cancer
Treatment of cancer primarily consists of surgery, radiation, and chemotherapy. The most common rationale for the use of chemotherapy is to control the cell population by cell-kill mechanism. Current chemotherapy consists of cytotoxic (cell-killing) agents and anti-hormonal drugs, which reduce the proliferative drive of the tumour. Many compounds with good cell-killing activity have been discovered, but few have found clinical utility. The lack of discrimination between a malignant (tumour) and normal tissue is one of the major hurdles. The cell-cycle dependency of many cytotoxic drugs and their frequent susceptibility to induce drug resistance and significant side-effects are the difficulties often encountered during chemotherapy. The cell division in malignant cells occur at a much faster rate in comparison to the normal cells and thus provides a potential target area for the development of chemotherapeutic agents. The role of chemotherapy is now apparent, in the effective treatment of a majority of solid tumours, as an adjuvant to initial therapy by surgical or radiotherapeutic procedures. Chemotherapy becomes critical for effective treatment for the reason that, only systemic therapy can cure micrometastases. The chemotherapeutic agents can be categorized based on their mode of action, like alkylating agents, antimetabolites, antibiotics and antimitotics. 
Pyrrolo[2,1-c][1,4]benzodiazepines as anticancer agents
The pyrrolo[2,1-c][1,4]benzodiazepines (PBDs) belonging to the class of DNA-interactive antitumour antibiotics have the potential as regulators of gene expression with possible therapeutic application in the treatment of genetic disorders including cancer. The first PBD antitumour antibiotic anthramycin has been described by Leimgruber et. al. in 1963, and since then a number of compounds have been developed based on PBD ring system leading to DNA binding ligands.

Figure 1
Pyrrolo[2,1-c][1,4]benzodiazepines (PBDs) are a family of potent naturally occurring low molecular weight antitumour antibiotics originally isolated from various Streptomyces species. A number of naturally occurring and synthetic compounds based on PBD ring system, such as anthramycin, tomaymycin, DC-81 (Figure 1) and its dimers (presently SJG-136 is under clinical evaluation), have shown varying degrees of DNA binding affinity and anti-cancer activity. Their interaction with DNA has been extensively investigated and it is considered unique since they bind within the minor groove of DNA forming a covalent aminal bond between the C11-position of the central B-ring and the N2 amino group of guanine base (Fig. 2)




CHAPTER - II
A New Class of Cinnamido linked Pyrrolo[2,1-c][1,4]benzodiazepine Conjugates and their Dimers as Anti-mitotic Agents 
Most chemotherapeutic anti-cancer drugs used in the clinic today include agents that target the cell cycle in order to inhibit the hyperproliferation state of tumor cells and subsequently to induce apoptosis, which is the desired outcome of chemotherapy. Based on their mode of action these chemotherapeutic drugs can be subdivided into distinct groups: 
	Drugs that interfere with DNA synthesis 
	Drugs that introduce DNA damage  
	Drugs that inhibit the function of the mitotic spindle 
The latter have been proven to be exceptionally successful in the clinic and are classically represented by microtubule binding drugs frequently referred to as spindle poisons. These drugs, which include taxanes and various Vinca alkaloids, bind to and inhibit the function of microtubules of the mitotic spindle apparatus, which leads to a stop of the cell cycle in mitosis and subsequently to the induction of tumor cell death.
Therefore, novel drug targets that spare microtubules, but inhibit the progression of mitosis are highly desired and already exploited for the development of novel anti-mitotic drugs. Thus, current drug development programs focus not only on improved novel anti-microtubule drugs, but also on novel mitotic drug targets that include mitotic kinesins and mitotic kinases. In addition, the use of drugs that abrogate the cell cycle arrest imposed by DNA damaging agents leading to an unscheduled entry into mitosis in the presence of DNA damage is a promising strategy to induce mitosis-associated cell death in tumor cells.
Recently, Jeh-Jeng Wang and co-workers have shown that a PBD hybrid (IN6CPBD)  agent can activate the apoptotic pathway mediated by mitochondria  and reported that induction of apoptosis by DC-81-indole conjugate agent through NF-KB and JNK/AP-1 pathway.
Based on the previous findings and new mechanisms, this research has been prompted for the synthesize of a series of C-8 linked cinnamido-pyrrolo[2,1-c][1,4]benzodiazepine monomers and their dimers. This is moreover in context towards the interest in the structural modifications and development of new synthetic strategies.
The synthesis and biological activities of PBDs that are linked to the cinnamido moiety through different alkyl chain spacers at C-8 position is described. Interestingly, these cinnamido-PBD conjugates and their dimers have shown significant in vitro cytotoxicity (nM concentration in some selected cell lines) and some compounds among them exhibit inhibition of tubulin polymerization leading to a stop of the cell cycle in mitosis and subsequently to the induction of tumor cell death. 
Synthesis of Cinnamido linked Pyrrolo[2,1-c][1,4]benzodiazepine Conjugates 
The synthetic pathway (Scheme 1) starts from commercially available 3,4,5-trimethoxy benzoic acid, which was treated with sulphonyl chloride and then coupled to N-bocpiperazine in the presence of a base to give the corresponding coupled compound 2. Further deprotection of boc by employing TFA in CH2Cl2 gave compound 3 and then coupled with E 4-hydroxy-3-methoxycinnamic acid chloride to give the required intermediate 4.
Morpholine in dry THF in the presence of triethylamine was added E 4-hydroxy-3-methoxy cinnamic acid chloride to give compound 5. Further the piperazine in dry THF in the presence of a base was added to the E 4-hydroxy-3-methoxy cinnamic acid chloride to give the dimer intermediate compound 6 as shown in Scheme 2.







Synthesis of cinnamido-pyrrolo[2,1-c][1,4]benzodiazepine (PBD) conjugates 12a-d and 13a-d and their dimers (16a-d) has been carried out by employing, (2S)-N-(4-benzyloxy-5-methoxy-2-nitrobenzoyl)pyrrolidine-2-carboxaldehyde diethyl thio- acetal 17 as one of the starting material. This has been prepared by the method reported in the literature. This upon debenzylation gives (2S)-N-(4-hydroxy)-5-methoxy-2-nitrobenzoyl)pyrrolidine-2-carboxaldehyde diethylthioacetal 18. After etherification of hydroxyl group of the above compound with dibromoalkanes gives (2S)-N-[(n-bromoalkyloxy)-3-methoxy-2-nitrobenzoyl)]pyrrolidine-2-carboxaldehy- dediethyl thioacetal 7a-d. Further coupling of them with compounds 4, 5 and 6 in the presence of K2CO3 in acetonitrile gives the desired intermediate nitro compounds (2S)-{[methyl4-[3-[4-(methoxycarbonyl)benzyl]oxy-5-(piperazinometh -yl)phenoxy]methylbenzoate]butyloxy-5-methoxy-2-nitrobenzoyl}pyrrolidine-2- carboxaldehyde diethyl thioacetals 8a-d, 9a-d and 14a-d respectively which upon reduction  with SnCl2.2H2O gives 10a-d, 11a-d and 15a-d. The deprotection of these thioacetals by employing HgCl2/CaCO3 affords the target imine compounds 12a-d, 13a-d and 16a-d (Schemes 3 and 4). 











A new series of cinnamido-pyrrolo[2,1-c][1,4]benzodiazepine conjugates 12a-d, 13a-d and dimers (16a-d) with different linker architectures have been designed, synthesized and evaluated for their biological activities such as DNA-binding affinity and cytotoxicity. The anti-proliferative profile of compound 4a has been evaluated for its anticancer activity against 60 human cancer cell lines. 
This compound has shown significant potent with GI50 values ranging from 68-732 nM towards 53 out of 60 human cancer cell lines tested; particularly it is active at <90 nM in CCRF-CEM (leukemia), NCI-H522 (Non-small cell Lung Cancer), MCF7 & MDA-MB-455 (Breast Cancer). In PBD monomers 13a, 13c & 13d and in PBD dimers 16a, 16c & 16d have shown remarkable cytotoxic activity with GI50 values were <10-7 M concentrations in a number cell lines. DNA thermal denaturation studies suggested that these analogues have been promising DNA binding interactions compared to unsubstituted DC-81. These results demonstrated that the conjugation of cinnamido component to the PBD has been remarkably enhanced cytotoxic activity and DNA binding affinity. 
CHAPTER-III
Synthesis, DNA-binding ability and Biological Activity of C8 Linked G1 Dendrimer-Pyrrolobenzodiazepine Conjugates as Anticancer Agents

Dendrimers have been of great interest in the application to drug delivery systems; however their use in this area has remained largely unexplored. In recent years, several attempts have been made to design dendrimers as drug carriers. It has been shown that dendrimers can be combined to drug molecules via a covalent bond. For example, Zhuo and coworkers have synthesized the polyamidoamine (PAMAM) dendrimers with a cyclic core and linked them to an anticancer drug like 5-fluorouracil. Similarly polyether dendritic compounds bearing folate residues on their surface have been prepared as model drug carriers with potential tumor cell specificity. Further methotrexate (MTX) has been conjugated to the chain ends of hydrazide terminated poly(aryl ether)dendrimers.
During the last decade, many piperazine derivatives have been synthesized as useful chemotherapeutic agents. Michejda and co-workers reported symmetrical bifunctional agents that possess a piperazine moiety in its linker spacer as promising class of antitumour compounds with remarkable selectivity against colon cancer. Studies in this laboratory on the PBD dimers incorporating a piperazine moiety in their alkane spacer linker exhibited enhanced DNA binding ability as well as promising anticancer activity. It has been observed that the inclusion of a piperazine moiety in these compounds has enhanced the DNA binding ability to a significant extent probably due to their non-covalent interactions that could take place by this moiety in the minor groove of DNA. In continuation of these efforts and interest in this laboratory on the development of new structurally modified PBD molecules as well as new synthetic stratagies for their preparation. Synthesis of PBD linked to a G1 poly (aryl ether) dendrimerhas been investigated. The linkage between these conjugates has been carried out by various alkane spacers at C-8 position of the PBD ring to the dendrimer through a piperazine moiety with a view to enhance their lipophilicity as well as biological activity.
Based on previous studies on dendrimers and their interesting biological applications like as drug carrier property, targeting on DNA, gene delivery, cancer diagnosis, and solubilization property prompted to synthesize a series of new pyrrolo[2,1-c][1,4]benzodiazepine-G1 poly (aryl ether) dendrimer hybrids. It has been observed that the incorporation of piperazine moiety between dendrimer and PBD has shown significant enhancement in the DNA binding ability
Synthesis of C8 Linked G1 Dendrimer-Pyrrolobenzodiazepine Conjugates 
The dendritic benzyl bromide 4 has been prepared as shown in Scheme 1 by employing the reported procedure.  Further, this upon coupling with boc-protected piperazine followed by deprotection provides the required key intermediate methyl 4-[3-[4-(methoxycarbonyl)benzyl]oxy-5-(piperazinomethyl)phenoxy]methylbenzo- ate 6 (Scheme 1).




Synthesis of G1 dendrimer-pyrrolo[2,1-c][1,4]benzodiazepine (PBD) conjugates 12a-d has been carried out by following methods, (2S)-N-(4-benzyloxy-5-methoxy-2-nitro benzoyl) pyrrolidine-2-carboxaldehydediethylthioacetal 6 as one of the starting material. This has been prepared by the method reported in the literature. This upon debenzylation gives (2S)-N-(4-hydroxy)-5-methoxy-2-nitro- benzoyl)pyrrolidine-2-carboxaldehyde diethyl thioacetal. After etherification of hydroxyl group of the above compound with different dibromo alkanes give (2S)-N-[(n-bromoalkyloxy)-3-methoxy-2-nitrobenzoyl)]pyrrolidine-2-carboxaldehyde diethyl thioacetals 12a-d. Further coupling of them with compound 6 in the presence of K2CO3 in acetonitrile gives the desired intermediate nitro compound (2S)-{[methyl4-[3-[4-(methoxycarbonyl)benzyl]oxy-5-(piperazinomethyl)phenoxy] methylbenzo-ate]butyloxy-5-methoxy-2-nitrobenzoyl}pyrrolidine-2-carboxaldehyde diethyl thioacetals 10a-d, which upon reduction with SnCl2.2H2O gives 11a-d. The deprotection of these thioacetals by employing HgCl2/CaCO3 affords the target imine compounds 12a-d (Scheme 2) 




The DNA binding affinity of these G1 dendrimer-PBD conjugates 12a-d and 13a-d has been investigated by the thermal denaturation studies using calf thymus (CT) DNA duplex at pH 7.0. Interestingly, these compounds 12a-d and 13a-d elevate the helix melting temperature of CT-DNA in the range 3.2-19.0 oC after 18 h incubation at 37 oC. The Tm value for one of the PBD-dendrimer conjugate (12b) is highly significant and shows that this compound provides a favourable interaction with DNA which has a four carbon spacer between C-8 position of PBD and the piperazine moiety.
Compounds 12a-c have been evaluated for their in vitro cytotoxicity in selected human cancer cell lines like Hop62 (lung), SiHa (cervix), MCF7 and ZR75-1 (breast), Colon205 (colon), PC3 (prostate) and A2780 (ovarian) by employing the sulforhodamine B (SRB) assay. The GI50 value is a response parameter and represents the concentration of the compound that induces 50% cell line growth inhibition. When the concentration of the compound is less than or equal to 10-5 mol/L, and the growth inhibition 50% or more, then the compound is considered as an effective agent. According to this standard, it has been observed from Table 2 that compounds 12a-c exhibit significant cytotoxic activity against some of the cell lines and the activity was comparable with adriamycin (ADR). Therefore, it appears that incorporation of G1 poly (aryl ether) dendrimer to a PBD ring system through a piperazine moiety enhances the cytotoxic potency. For example the GI50 values for compound 12c exhibits strong effect in some of these cell lines 0.20 (A-549), 0.16 (DWD), 0.17 (A2780) and 0.16 (colo 205) μM. Moreover, the in vitro cytotoxicity (GI50) for naturally occurring DC-81 is 0.38, and 0.33 μM in L1210 and PC-3 cell lines.
CHAPTER-IV
In current research, combination chemotherapy with different mechanisms of action is one of the methods that are being adopted to treat cancer. Therefore, a single molecule containing more than one pharmacophore, each with different mode of action could be beneficial for the treatment of cancer. The imine or carbinolamine-containing pyrrlo[2,1-c][1,4]benzodiazepines are a family of low molecular weight antitumour antibiotics originally isolated from various Streptomyces species. These antibiotics bind selectively in the minor groove of DNA through a covalent aminal bond between the electrophilic C11 position of the PBD moiety and the nucleophilic N2-amino group of a guanine base, resulting in the possible biological activity. It has been observed that the contribution by such non-covalent component plays an important role in the overall DNA binding affinity in such mixed-type of PBD dimers. During the course of efforts directed towards the development of new anticancer agents in this laboratory, it is observed that some new molecules based on PBD linked conjugates like PBD-chalcones exhibited potential anticancer activity. Chalcones have received significant attention for their antitumour properties over the last few years, particularly in view of their similar mode of action to the structurally related combretastatin. The anticancer activity of certain chalcones, known to result in binding to tubulin and prevent it from polymerizing microtubules, are the targets for a number of clinical useful anticancer compounds including natural products like paclitaxel, vincristine, and colchicine.
These findings provided further impetus to explore the combination of certain non-covalent interacting groups with a PBD moiety that led to the design and synthesis of a variety of PBD hybrids. The research in this direction in this laboratory afforded a number of such PBD hybrids with enhanced DNA binding ability and significant anticancer potential. In continuation of these efforts and above said aspects it has been considered of interest to design and synthesis molecules based on PBD linked to 1,4-diarylimidazolinones.
Synthesis of 1,4-diarylimidazolinone linked pyrrolobenzodiazepine hybrids 
The synthesis of intermediates 6a-r has been carried out as shown in Scheme 1. The coupling of 3,4,5-trimethoxy aniline (1) with different substituted phenacyl bromides (2a-g) afford the corresponding compounds (3a-g), which upon cyclization in the presence of potassium isocyanato gives the 1,4-diarylimidazole-2-ones (4a-g). Then these imidazolones on Pd/C under hydrogen pressure gives the imidazolidinones (5a-g). These compounds have been further reaction with dibromoalkanes in the presence of anhydrous K2CO3 resulted the intermediate compounds (6a-r)
Compound 7 has been coupled to compounds 6a-r to produce corresponding 8a-r. These coupled nitrothioacetal intermediates 8a-r upon reduction with SnCl2.2H2O in methanol gives the aminothioacetal precursors 9a-r and these on deprotection by HgCl2/CaCO3 affords the desired PBD hybrids 10a-r (Scheme 2).




In conclusion the thesis describes the development of pyrrolo[2,1-c][1,4]benzodi-azepine conjugates and their dimers as potential DNA interactive, anticancer agents with antimitotic and inhibition of tubulin polymerization properties.



